Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Plant-Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

  • Lozano-Sánchez, Enrique|||0009-0000-1655-9296
  • Daròs, José-Antonio|||0000-0002-6535-2889
  • Moreno-Gonzalez, Miguel A.
  • Steinmetz, Nicole F.
  • Merwaiss, Fernando
[EN] Potato virus X (PVX), a filamentous, positive-sense RNA plant virus, has been engineered into a molecular tool for diverse biotechnological applications, including cancer cell targeting. Here, we present the production and functional characterization of genetically-encoded PVX-derived nanoparticles decorated with nanobodies targeting two common receptors in human cancer cells, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2). We first generated a series of PVX-derived nanoparticles displaying distinct nanobodies against EGFR and HER2 in Nicotiana benthamiana plants. Self-assembly and structural integrity of the recombinant nanoparticles were confirmed by immunogold electron microscopy. We next characterized in vitro the cancer-cell binding capacity of the different recombinant viral nanoparticles (VNPs) by flow cytometry and confocal microscopy. Select VNPs were further assayed in a pilot in vivo study using tumor-bearing mice. Preliminary results showed that nanobody decoration can increase retention time and myeloid cell recruitment in the tumor microenvironment in HER2+ mouse tumor models in vivo. Nanobody-displaying PVX-derived nanoparticles may constitute a new plant-produced biotechnological product for cancer immunotherapy., This research was funded by the Ministerio de Ciencia, Innovacion y Universidades (MCIU; Spain) through the Agencia Estatal de Investigacion (PID2023-146418OB-I00; PDC2025-165423-I00; MICIU/AEI/10.13039/501100011033 and ERDF, EU), Generalitat Valenciana through program PROMETEO (CIPROM/2022/21), and in part through grants from the National Institutes of Health, NCI R01 CA224605, NCI R01-CA253615, and NCI R01-CA253615-02S1 Supplement. E.L-S. is the recipient of a predoctoral contract (PRE2021-097401) from MICIU (Spain).